Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities

12 Months Ended

Dec. 31, 2014

Selected cash payments, receipts, and noncash activities are as follows (in thousands):



	Twelve Months Ended December 31,
	2014		2013		2012
Cash paid for interest	$	48	$	36	$	13
Income taxes paid	384		61		—
Purchases of equipment financed through capital leases	—		355		85
Stock issuance of 167,086 shares in lieu of Directors' fees	—		—		184
Deferred financing costs	—		27		20
Beneficial conversion related to Line of Credit with related party	—		—		514
Stock issuance in connection with Earn-Out Liability of 1,174,915 shares for 2013 and 2,632,576 shares for 2012	—		5,792		3,186
Stock issuance in exchange for convertible debt of 5,272,004 shares	—		5,272		—
Stock issuance of 1,403,630 shares for payment of Line of Credit with related party	—		—		1,403
Stock issuance of 15,958 shares in exchange for services performed	117		—		—
Stock issuance of 216,085 shares for exercise of cashless warrants	—		—		216
Stock issuance of 893,267 shares in payment of Convertible Secured Promissory Notes related to acquisition of Surgical Biologics	—		—		893
Tenant improvement incentive	—		997		—
Legal fees paid for public offering	—		102		—
Legal fees related to public offering included in accounts payable	—		30		—
Legal fees related to public offering included in accrued expenses	—		62		—